**Supplemental Table 2. Detailed Information of Every Single Patient with Hemoptysis.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Patient | Periods between the onset of CTEPH symptoms and hemoptysis\*, years | Specific therapy of CTEPH | Follow-up period after hemoptysis onset, months | Cause of death | Time of relapse, days |
| BAE patients | | | | | |
| 1 | 4.77 | CCB, PEA | 15.77 | - | - |
| 2 | 1.10 | CCB | 13.86 | - | - |
| 3 | 2.03 | Macitentan | 10.81 | - | - |
| 4 | 0.67 | Tadalafil | 10.91 | - | - |
| 5 | 11.98 | Riociguat | 7.59 | - | - |
| 6 | 8.34 | Sildenafil | 5.26 | - | 121 |
| 7 | 1.69 | Sildenafil+ treprostinil | 4.80 | - | - |
| 8 | 0.81 | CCB, PEA after BAE | 3.81 | - | - |
| 9 | 2.95 | Tadalafil | 1.18 | Retroperitoneal hemorrhage after renal radical resection | - |
| 10 | 5.11 | Tadalafil | 26.61 | - | 20 |
| Non-BAE patients | | | | | |
| 1 | 2.32 | Tadalafil+ ambrisentan | 5.13 | Catastrophic antiphospholipid syndrome + lung infection | 125 |
| 2 | 5.85 | - | 0.95 | Hemoptysis | 29 |
| 3 | 2.04 | Treprostinil | 0.43 | Hemoptysis | 13 |
| 4 | 15.26 | Ambrisentan + treprostinil | 14.78 | - | - |
| 5 | 1.94 | - | 34.69 | - | 49 |

\*The common symptoms of CTEPH include shortness of breath, fatigue, weakness, angina, syncope and dry cough, which are typically induced by exertion. CTEPH = chronic thromboembolic pulmonary hypertension, BAE = bronchial artery embolization, CCB = calcium channel blockers, PEA = pulmonary endarterectomy.